Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Neuland Laboratories Ltd

₹ 14,087-1.23%
16 Jan – close price
🔗neulandlabs.com•BSE: 524558•NSE: NEULANDLAB
Market Cap₹ 18,065 Cr.
Current Price₹ 14,087
High / Low₹ 19,748
Stock P/E92.7
Book Value₹ 1,257
Dividend Yield0.09 %
ROCE18.7 %
ROE14.8 %
Face Value₹ 10.0
Sales₹ 1,533 Cr.
OPM21.3 %
Mar Cap₹ 18,065 Cr.

ABOUT

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]

KEY POINTS

Business Segments1. Prime APIsThis segment comprises ~15 mature large volume APIs in a highly competitive market. The key molecules in this primary revenue generating segment are Levetiracetam and Mirtazapine.[1]

Also present in buckets:
Aggressive Growth TriggersExcellent ResultsRevenue GuidanceAsset Base ExpansionCapacity Expansion And ProductsOrder Book PositionLarge Order ReceiptsRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1668.9034.69400460.330.963124.952.5614478.318.9320.2154964.0130.1211543.963117.955.1512.970.07
2.Divi's Lab.6236.0066.61165513.660.48689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.7413.530.01
3.Torrent Pharma.4018.2062.75135955.090.80591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.1013.260.33
4.Cipla1397.5020.75112878.160.931353.373.737589.447.6422.7228349.5725.405441.141351.173.4314.720.01
5.Lupin2177.9023.0199527.000.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.0712.410.32
6.Dr Reddy's Labs1175.5017.0098114.930.681336.807.288828.309.8322.6934310.0024.645772.201347.102.7212.950.16
7.Mankind Pharma2175.4051.3789821.630.05520.18-22.003697.1620.7715.9813545.6724.121748.55511.515.878.890.55
8.Neuland Labs.14087.0092.6718065.360.0996.46201.81514.2765.4518.681533.4121.30194.9596.4611.2110.350.16
–Median: 149 Co.392.630.01767.160.1213.9610.46161.7610.5814.89603.8515.9345.2614.123.138.560.22

Quarterly Results

Standalone figures in ₹ crores

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
294269407363418393385440311398328293514
Expenses
225215287266280272278316250312278258359
Operating Profit
69541209713712110712461865134155
Other Income
018232525460782
Profit before tax
53391108412110492130491283917129
Tax %
28%22%23%25%27%22%27%25%34%20%29%21%25%
Net Profit
383085628981689832101281496
EPS in Rs
29.8823.7365.8748.5069.4262.9052.7076.6524.9179.0321.6110.6975.18

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
4664695105795276677639379511,1911,5591,4771,533
Expenses
3954024304734776096617908079191,0961,1471,207
Operating Profit
7067801065058101147144272462330327
Other Income
30214341609129077
Interest
2527242119162218131314814
Depreciation
15151619222631404953606676
Profit before tax
3424416714205210582215401345313
Net Profit
271626461216168064163300259239
EPS in Rs
29.9717.7629.7352.2013.2912.5812.3862.5849.52127.14233.52202.21186.51
Dividend Payout %
9%9%7%0%0%0%16%8%10%8%6%6%–

Compounded Sales Growth

10 Years:12%
5 Years:14%
3 Years:16%
TTM:0%

Compounded Profit Growth

10 Years:29%
5 Years:67%
3 Years:47%
TTM:-26%

Stock Price CAGR

10 Years:35%
5 Years:63%
3 Years:105%
1 Year:3%

Return on Equity

10 Years:12%
5 Years:16%
3 Years:20%
Last Year:15%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
899991313131313131313
Reserves
1151511755345466836937698239751,2641,5051,599
Borrowings
19018818219231923126418224112895157265
Other Liabilities
171164157150197203260359306463459503655
Total Liabilities
4835115238851,0711,1301,2301,3241,3821,5791,8312,1782,532
Fixed Assets
1311231394664755416537167677588249551,076
Gross Block
2592642924855136057468459369731,0931,238–
Accumulated Depreciation
12814115319386493130169215269283–
CWIP
35414020126104241720414648140
Investments
88888887411109114
Other Assets
3103393373924624765455835907819601,0661,202
Total Assets
4835115238851,0711,1301,2301,3241,3821,5791,8312,1782,532

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
4913453912705718960239260317
Cash from Investing Activity
-10-14-20-42-116-77-49-84-96-62-150-298
Cash from Financing Activity
-391-24-010512-5-11438-136-6925
Net Cash Flow
001-3042-93414144

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
9310085114134909185901118778
Inventory Days
138170182188268191209205227211220238
Days Payable
138167124123198123114130105135125161
Cash Conversion Cycle
93103144179205158186160212187183155
Working Capital Days
-22924423642475972788774
ROCE %
19%16%18%16%4%4%8%11%10%21%33%19%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters
36.14%36.14%36.03%35.97%32.80%32.74%32.72%32.64%32.68%32.67%32.67%32.64%32.63%
FIIs
17.70%18.14%20.19%21.57%22.69%24.43%25.72%26.46%23.86%22.12%21.69%20.60%20.90%
DIIs
6.54%7.10%6.76%6.99%6.02%6.54%6.39%6.38%9.09%10.97%11.57%13.55%14.72%
Public
39.15%38.22%36.62%35.08%38.10%35.88%34.77%34.12%33.96%33.85%33.67%32.80%31.76%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Neuland Labs Re-launches 'Saksham Niveshak' Campaign for Investors

14th April 2026, 4:18 pm

Davuluri Trust Confirms SEBI Compliance for Neutand Labs for FY2026

9th April 2026, 9:59 pm

Neuland Laboratories Files SEBI Compliance Certificate for Q4 FY26

2nd April 2026, 8:44 pm

Neuland Labs Appoints Saharsh Davuluri as CEO & MD to Spearhead CDMO Expansion

1st April 2026, 7:13 pm

Neuland Labs Promoter Davuluri Saharsh Rao Pledges 0.75% Stake for Personal Borrowing

27th March 2026, 10:47 pm

Published by Other Websites

External media mentions & references

Vijay Kedia Stocks Tumble: 6 Holdings Down 25-45%

25th March 2026, 12:41 pm

Indian Markets Plummet 2% on Crude Spike, Geopolitical Fears

2nd March 2026, 1:50 pm

Pharma Rally: Nuvama Buys 5, but Valuations and Risks Loom

11th February 2026, 4:25 pm

JM Financial's 10 Growth Picks: Value or Volatility?

11th February 2026, 6:11 am

Neuland Labs Profit Halved as Sales Slump, Costs Sap Margins

9th February 2026, 5:21 pm

News Articles

Editorial & research coverage

Pharma Rally: Nuvama Buys 5, but Valuations and Risks Loom
Pharma Rally: Nuvama Buys 5, but Valuations and Risks Loom

11th February 2026, 4:25 pm

JM Financial's 10 Growth Picks: Value or Volatility?
JM Financial's 10 Growth Picks: Value or Volatility?

11th February 2026, 6:11 am

Neuland Labs Profit Halved as Sales Slump, Costs Sap Margins
Neuland Labs Profit Halved as Sales Slump, Costs Sap Margins

9th February 2026, 5:21 pm

India's Pharma Revolution: Govt Triggers Local API Boom, Smashing China Dependence & Igniting Stock Surges!
India's Pharma Revolution: Govt Triggers Local API Boom, Smashing China Dependence & Igniting Stock Surges!

20th December 2025, 6:16 am

Indian Markets Tumble! Small & Midcaps Face Steep Sell-Off – What's Driving the Shock?
Indian Markets Tumble! Small & Midcaps Face Steep Sell-Off – What's Driving the Shock?

16th December 2025, 12:58 pm

Documents

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

2 Jan - Certificate under SEBI Regulation 74(5) for quarter ended Dec 31, 2025, furnished by Kfin.

Re-Lodgement Of Transfer Request Of Physical Shares

2 Jan - Re-lodgement report for physical share transfers for month ended Dec 31, 2025; KFin reports no approvals/rejections.

Closure of Trading Window
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

15 Dec 2025 - About Schedule of Analyst / Institutional Investor Meeting on December 18, 2025

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from nse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Credit Ratings

Rating update

20 Jun 2025 from crisil

Rating update

7 May 2025 from fitch

Rating update

10 Mar 2025 from fitch

Rating update

27 Mar 2024 from crisil

Rating update

14 Feb 2024 from fitch

Rating update

8 Feb 2024 from fitch

Concalls

Nov 2025

TranscriptPPTRecording

Aug 2025

TranscriptPPTRecording

May 2025

TranscriptPPTRecording

Feb 2025

TranscriptPPTRecording

Nov 2024

TranscriptPPTRecording

Aug 2024

TranscriptPPTRecording

May 2024

TranscriptPPT

May 2024

PPT

Feb 2024

TranscriptPPT

Nov 2023

TranscriptPPT

Aug 2023

TranscriptPPTRecording

May 2023

TranscriptPPTRecording

Feb 2023

TranscriptPPT

Feb 2023

PPT

Nov 2022

TranscriptPPT

Nov 2022

PPT

Aug 2022

TranscriptPPT

May 2022

Transcript

Feb 2022

TranscriptPPT

Oct 2021

TranscriptPPT

Aug 2021

TranscriptPPT

May 2021

Transcript

Feb 2021

TranscriptPPT

Nov 2020

TranscriptPPT

Jul 2020

Transcript

May 2020

Transcript

Jan 2020

Transcript

Nov 2019

Transcript

Aug 2019

Transcript

Feb 2019

Transcript

Nov 2018

Transcript

Oct 2018

Transcript

May 2018

Transcript

Jan 2018

Transcript

Nov 2017

Transcript

Sep 2017

Transcript

May 2017

Transcript

Feb 2017

Transcript

Nov 2016

Transcript

Aug 2016

Transcript

May 2016

Transcript

Stock Analysis

Description

Neuland Laboratories is an Indian pharmaceutical company specializing in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs) and intermediates, serving both domestic and international markets.

Key Growth Triggers

  1. Strong Q2 FY26 performance driven by Contract Manufacturing Services (CMS) and margin expansion.
  2. Major API supply contracts worth ₹5,800 crore over five years with US clients and ₹800 crore with ETN Pharma US, LLC.
  3. US FDA approval for a key drug substance, expanding market potential.
  4. Investment of ₹189 crore in a new R&D center to bolster research capabilities.
  5. Commencement of commercial production at Unit 3 and planned leadership changes to support growth.

Order Book

While no specific order book figure is provided, the company has secured long-term API supply agreements with US clients totaling ₹5,800 crore over five years and another deal worth ₹800 crore with ETN Pharma US, LLC, indicating significant future revenue visibility.

Key Red Flags

  1. Q1 FY26 performance showed a significant YoY revenue drop of 32.4% and worsening working capital, leading to negative free cash flow in H1 FY26.
  2. Historical data suggests high valuation metrics (P/E ~99, P/B ~12), which could be a concern for investors.

Key Dates To Watch

  1. Q3 FY26 financial results announcement and earnings call scheduled for November 7, 2025.
  2. Leadership role re-designations effective April 1, 2026, pending shareholder approval.
  3. Ongoing investor outreach programs and participation in industry events.

Corporate Announcements

14th Apr 26
Impact Rating: -
No description available.
9th Apr 26
Impact Rating: 5
Davuluri Ownership Trust received a compliance certificate for the financial year ended March 31, 2026. This confirms adherence to a SEBI exemption order, demonstrating regulatory compliance for Neutand Laboratories.
2nd Apr 26
Impact Rating: 5
Neuland Laboratories Limited filed its SEBI Regulation 74(5) certificate for the quarter ended March 31, 2026, confirming dematerialization details from its registrar.
1st Apr 26
Impact Rating: 8
Effective April 1, 2026, Saharsh Davuluri becomes Neuland Laboratories' CEO & MD. He will focus on advancing the company's CDMO business and expansion initiatives.
27th Mar 26
Impact Rating: 6
Promoter Davuluri Saharsh Rao of Neuland Laboratories Limited disclosed pledging 96,000 shares (0.75% of total capital) for personal borrowing to Aditya Birla Money Limited on March 25, 2026, as per SEBI regulations.